Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Mar, 2016 | Pages:
193 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H1 2016', provides an overview of the Keratoconjunctivitis sicca (Dry Eye) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Keratoconjunctivitis sicca (Dry Eye), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Keratoconjunctivitis sicca (Dry Eye) and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Keratoconjunctivitis sicca (Dry Eye) - The report reviews pipeline therapeutics for Keratoconjunctivitis sicca (Dry Eye) by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Keratoconjunctivitis sicca (Dry Eye) therapeutics and enlists all their major and minor projects - The report assesses Keratoconjunctivitis sicca (Dry Eye) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Keratoconjunctivitis sicca (Dry Eye) Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Keratoconjunctivitis sicca (Dry Eye) - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Keratoconjunctivitis sicca (Dry Eye) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Keratoconjunctivitis sicca (Dry Eye) Overview 9 Therapeutics Development 10 Pipeline Products for Keratoconjunctivitis sicca (Dry Eye) - Overview 10 Keratoconjunctivitis sicca (Dry Eye) - Therapeutics under Development by Companies 11 Keratoconjunctivitis sicca (Dry Eye) - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Early Stage Products 17 Unknown Stage Products 18 Keratoconjunctivitis sicca (Dry Eye) - Products under Development by Companies 19 Keratoconjunctivitis sicca (Dry Eye) - Companies Involved in Therapeutics Development 23 AB2 Bio Ltd. 23 Akari Therapeutics, Plc 24 Allergan Plc 25 Circadian Technologies Limited 26 Delenex Therapeutics AG 27 Digna Biotech, S.L. 28 Dompe Farmaceutici S.p.A. 29 HanAll Biopharma Co., Ltd. 30 Herantis Pharma Plc 31 Huons Co., Ltd. 32 InSite Vision Incorporated 33 Kala Pharmaceuticals, Inc. 34 Kissei Pharmaceutical Co., Ltd. 35 Kukje Pharmaceutical Industry Co., Ltd. 36 Laboratorios Sophia S.A. de C.V. 37 Lee's Pharmaceutical Holdings Limited 38 Lipicard Technologies Limited 39 Merck & Co., Inc. 40 Mimetogen Pharmaceuticals Inc. 41 Mitotech S.A. 42 Nanomerics Ltd 43 Neuroptis Biotech 44 Novaliq GmbH 45 Ocular Therapeutix, Inc. 46 Oculis ehf 47 OncoNOx ApS 48 Otsuka Holdings Co., Ltd. 49 Parion Sciences, Inc. 50 PharmaReaserch Products Co., Ltd. 51 RegeneRx Biopharmaceuticals, Inc. 52 Rigel Pharmaceuticals, Inc. 53 Samjin Pharmaceutical Co., Ltd. 54 Santen Pharmaceutical Co., Ltd. 55 Seikagaku Corporation 56 Shire Plc 57 Sucampo Pharmaceuticals, Inc. 58 TearSolutions, LLC. 59 Xigen SA 60 Keratoconjunctivitis sicca (Dry Eye) - Therapeutics Assessment 61 Assessment by Monotherapy Products 61 Assessment by Target 62 Assessment by Mechanism of Action 65 Assessment by Route of Administration 68 Assessment by Molecule Type 70 Drug Profiles 72 AGN-223575 - Drug Profile 72 AGN-232411 - Drug Profile 73 AVX-012 - Drug Profile 74 Ax-8 - Drug Profile 75 BRM-421 - Drug Profile 76 cinhyaluronate sodium - Drug Profile 77 Cis-Urocanic Acid - Drug Profile 78 Cryosim-3 - Drug Profile 81 cyclosporine - Drug Profile 82 cyclosporine - Drug Profile 83 cyclosporine - Drug Profile 86 cyclosporine - Drug Profile 87 cyclosporine - Drug Profile 88 cyclosporine - Drug Profile 89 cyclosporine - Drug Profile 90 dexamethasone acetate SR - Drug Profile 91 diclofenac sodium - Drug Profile 92 diquafosol tetrasodium - Drug Profile 93 disitertide - Drug Profile 95 DLX-105 - Drug Profile 98 DMT-220 - Drug Profile 100 HL-036 - Drug Profile 101 HU-007 - Drug Profile 102 ISV-101 - Drug Profile 103 KeraKlear - Drug Profile 104 KJ-14003 - Drug Profile 105 KL-7016 - Drug Profile 106 KPI-190 - Drug Profile 107 Lacripep - Drug Profile 108 lifitegrast - Drug Profile 109 LME-636 - Drug Profile 112 loteprednol etabonate - Drug Profile 113 NOP-3 - Drug Profile 115 NOP-5 - Drug Profile 116 Nov-03 - Drug Profile 117 OC-301 - Drug Profile 118 OPX-1 - Drug Profile 119 OX-1001 - Drug Profile 120 ozagrel - Drug Profile 121 P-321 - Drug Profile 122 plastoquinone decyl triphenylphosphonium bromide - Drug Profile 123 PPL-003 - Drug Profile 125 PRD-005 - Drug Profile 127 PRO-148 - Drug Profile 128 Qi-204 - Drug Profile 129 R-348 - Drug Profile 130 rebamipide - Drug Profile 131 Recombinant Protein to Agonize p75NTR and Trk for Ophthalmology - Drug Profile 133 RGN-259 - Drug Profile 135 RP-101 - Drug Profile 137 RU-101 - Drug Profile 138 SA-001 - Drug Profile 139 tadekinig alfa - Drug Profile 140 tavilermide hydrochloride - Drug Profile 141 VGX-100 - Drug Profile 142 XG-104 - Drug Profile 145 ZK-003 - Drug Profile 146 zucapsaicin - Drug Profile 147 Keratoconjunctivitis sicca (Dry Eye) - Recent Pipeline Updates 149 Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects 177 Keratoconjunctivitis sicca (Dry Eye) - Discontinued Products 182 Keratoconjunctivitis sicca (Dry Eye) - Product Development Milestones 183 Featured News & Press Releases 183 Appendix 188 Methodology 188 Coverage 188 Secondary Research 188 Primary Research 188 Expert Panel Validation 188 Contact Us 188 Disclaimer 189
List of Tables
Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye), H1 2016 14 Number of Products under Development by Companies, H1 2016 16 Number of Products under Development by Companies, H1 2016 (Contd..1) 17 Number of Products under Development by Companies, H1 2016 (Contd..2) 18 Comparative Analysis by Late Stage Development, H1 2016 19 Comparative Analysis by Clinical Stage Development, H1 2016 20 Comparative Analysis by Early Stage Development, H1 2016 21 Comparative Analysis by Unknown Stage Development, H1 2016 22 Products under Development by Companies, H1 2016 23 Products under Development by Companies, H1 2016 (Contd..1) 24 Products under Development by Companies, H1 2016 (Contd..2) 25 Products under Development by Companies, H1 2016 (Contd..3) 26 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by AB2 Bio Ltd., H1 2016 27 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Akari Therapeutics, Plc, H1 2016 28 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Allergan Plc, H1 2016 29 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Circadian Technologies Limited, H1 2016 30 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Delenex Therapeutics AG, H1 2016 31 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Digna Biotech, S.L., H1 2016 32 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Dompe Farmaceutici S.p.A., H1 2016 33 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by HanAll Biopharma Co., Ltd., H1 2016 34 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Herantis Pharma Plc, H1 2016 35 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Huons Co., Ltd., H1 2016 36 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by InSite Vision Incorporated, H1 2016 37 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Kala Pharmaceuticals, Inc., H1 2016 38 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2016 39 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Kukje Pharmaceutical Industry Co., Ltd., H1 2016 40 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Laboratorios Sophia S.A. de C.V., H1 2016 41 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2016 42 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Lipicard Technologies Limited, H1 2016 43 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Merck & Co., Inc., H1 2016 44 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Mimetogen Pharmaceuticals Inc., H1 2016 45 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Mitotech S.A., H1 2016 46 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Nanomerics Ltd, H1 2016 47 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Neuroptis Biotech, H1 2016 48 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Novaliq GmbH, H1 2016 49 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Ocular Therapeutix, Inc., H1 2016 50 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Oculis ehf, H1 2016 51 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by OncoNOx ApS, H1 2016 52 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Otsuka Holdings Co., Ltd., H1 2016 53 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Parion Sciences, Inc., H1 2016 54 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by PharmaReaserch Products Co., Ltd., H1 2016 55 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by RegeneRx Biopharmaceuticals, Inc., H1 2016 56 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Rigel Pharmaceuticals, Inc., H1 2016 57 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Samjin Pharmaceutical Co., Ltd., H1 2016 58 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Santen Pharmaceutical Co., Ltd., H1 2016 59 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Seikagaku Corporation, H1 2016 60 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Shire Plc, H1 2016 61 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Sucampo Pharmaceuticals, Inc., H1 2016 62 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by TearSolutions, LLC., H1 2016 63 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Xigen SA, H1 2016 64 Assessment by Monotherapy Products, H1 2016 65 Number of Products by Stage and Target, H1 2016 67 Number of Products by Stage and Mechanism of Action, H1 2016 70 Number of Products by Stage and Route of Administration, H1 2016 73 Number of Products by Stage and Molecule Type, H1 2016 75 Keratoconjunctivitis sicca (Dry Eye) Therapeutics - Recent Pipeline Updates, H1 2016 153 Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects, H1 2016 181 Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects (Contd..1), H1 2016 182 Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects (Contd..2), H1 2016 183 Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects (Contd..3), H1 2016 184 Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects (Contd..4), H1 2016 185 Keratoconjunctivitis sicca (Dry Eye) - Discontinued Products, H1 2016 186
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
